Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy

Ann Oncol 2017; (doi:10.1093/annonc/mdx237) The sentence beginning ‘While this review was in editorial production…’ under the heading ‘Immunosuppressive factors for DCs in the TME’ has been amended from: (While this review was in editorial production, the findings in [99] were confirmed and cDC1 cells were found, in an experimentalmelanomamodel, to be key to chemoattract CD8+ T cells to the TME by means of CXCL9 and CXCL10 production. Also, CXCL9 and CXCL10mRNA in human 105 melanomas were found to correlate with a gene signature denoting cDC1 infiltrate.) To: (While this review was in editorial production, the findings in [57] were confirmed and cDC1 cells were found, in an experimental melanoma model, to be key to chemoattract CD8+ T cells to the TME by means of CXCL9 and CXCL10 production [99]. Also, CXCL9 and CXCL10 mRNA in human melanomas were found to correlate with a gene signature denoting cDC1 infiltrate.) Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapyAnnals of OncologyVol. 28PreviewDendritic cells (DCs) are the main professional antigen-presenting cells for induction of T-cell adaptive responses. Cancer cells express tumor antigens, including neoantigens generated by nonsynonymous mutations, but are poor for antigen presentation and for providing costimulatory signals for T-cell priming. Mounting evidence suggests that antigen transfer to DCs and their surrogate presentation on major histocompatibility complex class I and II molecules together with costimulatory signals is paramount for induction of viral and cancer immunity. Full-Text PDF Open Archive